Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $61.23 million. The enterprise value is $17.58 million.

Market Cap	61.23M
Enterprise Value	17.58M

Important Dates

The next estimated earnings date is Tuesday, May 7, 2024, after market close.

Earnings Date	May 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.74 million shares outstanding. The number of shares has decreased by -0.08% in one year.

Shares Outstanding	10.74M
Shares Change (YoY)	-0.08%
Shares Change (QoQ)	-0.55%
Owned by Insiders (%)	15.06%
Owned by Institutions (%)	22.49%
Float	7.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.43
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 16.18, with a Debt / Equity ratio of 0.01.

Current Ratio	16.18
Quick Ratio	n/a
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -34.10% and return on invested capital (ROIC) is -43.45%.

Return on Equity (ROE)	-34.10%
Return on Assets (ROA)	-32.20%
Return on Capital (ROIC)	-43.45%
Revenue Per Employee	n/a
Profits Per Employee	-$760,073
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.74% in the last 52 weeks. The beta is 1.40, so Lantern Pharma's price volatility has been higher than the market average.

Beta (1Y)	1.40
52-Week Price Change	+19.74%
50-Day Moving Average	6.64
200-Day Moving Average	4.66
Relative Strength Index (RSI)	39.20
Average Volume (30 Days)	322,103

Short Selling Information

The latest short interest is 497,300, so 4.63% of the outstanding shares have been sold short.

Short Interest	497,300
Short Previous Month	420,915
Short % of Shares Out	4.63%
Short % of Float	6.33%
Short Ratio (days to cover)	1.18

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-17.88M
Pretax Income	-15.96M
Net Income	-15.96M
EBITDA	-15.79M
EBIT	-15.96M
Earnings Per Share (EPS)	-$1.47

Full Income Statement

Balance Sheet

The company has $41.30 million in cash and $234,471 in debt, giving a net cash position of $41.07 million or $3.82 per share.

Cash & Cash Equivalents	41.30M
Total Debt	234,471
Net Cash	41.07M
Net Cash Per Share	$3.82
Equity / Book Value	40.91M
Book Value Per Share	3.81
Working Capital	40.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$14.35 million and capital expenditures -$18,734, giving a free cash flow of -$14.37 million.

Operating Cash Flow	-14.35M
Capital Expenditures	-18,734
Free Cash Flow	-14.37M
FCF Per Share	-$1.33

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.08%
Shareholder Yield	0.08%
Earnings Yield	-27.22%
FCF Yield	-24.49%

Analyst Forecast

The average price target for Lantern Pharma is $11.00, which is 91.97% higher than the current price. The consensus rating is "Buy".

Price Target	$11.00
Price Target Difference	91.97%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-18.13%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2